Biocon sees FY20 as a strong year in terms of generics biz growth in US

Name: Biocon sees FY20 as a strong year in terms of generics biz growth in US
Uploaded: 2019-04-26T08:00:20+00:00
Duration: 6 min 43 s
Channel: CNBC-TV18
Description: “Expect FY20 to be a strong year in terms of growth of our generics business in US, supported strongly with our API business” said Kiran Mazumdar Shaw, CMD, Biocon.

CNBC-TV18

“Expect FY20 to be a strong year in terms of growth of our generics business in US, supported strongly with our API business” said Kiran Mazumdar Shaw, CMD, Biocon.

Category

Be the first to comment

Recommended